Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN05450731
ISRCTN05450731
Completed
N/A

Paediatric onset study to assess the efficacy of insulin pump therapy using the MiniMed Paradigm® REAL-Time system during the first year of diabetes in children and adolescents with type 1 diabetes

Hannover Childrens Hospital (Hannoversche Kinderheilanstalt) (Germany)0 sites160 target enrollmentJuly 31, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Hannover Childrens Hospital (Hannoversche Kinderheilanstalt) (Germany)
Enrollment
160
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 31, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hannover Childrens Hospital (Hannoversche Kinderheilanstalt) (Germany)

Eligibility Criteria

Inclusion Criteria

  • •1\. Provided written informed consent
  • •2\. Aged between 1 (inclusive) and 17 (exclusive) years (either sex) and diagnosed with type 1 diabetes at latest 4 weeks prior to study entry
  • •3\. Patients must be willing to use the MiniMed Paradigm® REAL\-Time system or MiniMed Paradigm® 515/715 insulin pump combined to conventional SMBG finger sticks for 12 months
  • •4\. Patients must be able and willing to perform at least two SMBG finger sticks daily
  • •5\. Patients are willing to undergo all study procedures
  • •6\. Training on how to adapt their insulin dose to their meals and awareness of how to calculate and apply corrective insulin boluses as well as of the influence of physical activity and their life style factors on their metabolic control
  • •7\. Patients are willing to participate to the MiniMed Paradigm® REAL\-Time system (Group A) and to the MiniMed Paradigm® 515/715 plus the Guardian REAL\-Time Clinical (Group B)

Exclusion Criteria

  • •1\. Hearing or vision impairment so that alarms cannot be recognised
  • •2\. Patient does not have reliable support person or is unwilling to comply with the provisions of the protocol
  • •3\. Mental incapacity
  • •4\. Language barriers precluding adequate understanding or cooperation
  • •5\. Patients suffering from severe chronic disease or genetic disorder other than type 1 diabetes (i.e. Down syndrome, etc.)
  • •6\. Pregnancy
  • •7\. Eating disorders
  • •8\. Alcohol or drug abuse other than nicotine
  • •9\. Patients participating in other device or drug related studies
  • •10\. Patients disclaimer of study participation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
Phase 3
Assessment of praziquantel medication for children living in areas where schistosomiasis is common in Bahia and Sergipe
RBR-86kcy37Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)
Not Yet Recruiting
N/A
Homoeopathy for VitiligoHealth Condition 1: L80- Vitiligo
CTRI/2022/03/041296Dr Neha Singhal
Completed
N/A
Clinical evaluation of the effects of paediatric dental general anaesthesia and midazolam sedation on cognitive function, anxiety and access to future dental careDental caries requiring multiple extractionsOral HealthCaries
ISRCTN12026431Scottish Executive Chief Scientist Office (UK)200
Active, Not Recruiting
Phase 1
A PAEDIATRIC PHASE I/II STUDY OF INTERMITTENT DOSING OF THE MEK-1 INHIBITOR SELUMETINIB IN CHILDREN WITH NEUROFIBROMATOSIS TYPE-1 AND INOPERABLE PLEXIFORM NEUROFIBROMA AND/OR PROGRESSIVE OPTIC PATHWAY GLIOMANeurofibromatosis type 1 associated plexiform neurofibromas Neurofibromatosis type 1 associated progressive or relapsed optic pathway gliomaMedDRA version: 20.0 Level: LLT Classification code 10029270 Term: Neurofibromatosis, type 1 (von Recklinghausen's disease) System Organ Class: 100000004850MedDRA version: 20.0 Level: LLT Classification code 10065866 Term: Plexiform neurofibroma System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10030935 Term: Optic nerve glioma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2017-002635-41-GBGreat Ormond Street Hospital38
Completed
N/A
Prospective clinical study in children with severe haemophilia A to investigate clinical efficacy, immunogenicity, pharmacokinetics, and safety of Human-cl rhFVIIISevere haemophilia AHaematological DisordersHaemophilia
ISRCTN71212110Octapharma AG (Switzerland)60